Villegas VCA, Arango PMC

Language: Spanish
References: 28
Page: 23-32
PDF size: 92.83 Kb.

ABSTRACT

Regulatory T cells (Treg) lymphocytes are a subpopulation of lymphoid cells whose function is the regulation of the immune system. These cells have suppressor functions involved in the development and monitoring of malignancies. In ovarian cancer, an increase of Treg in tumor microenvironment and systemic circulation has been shown. The objective of this paper is to update the knowledge related to immune system involvement in ovarian cancer. Document review was used, through information search engines available on Hinari. The increase of Treg lymphocytes in the tumor microenvironment and systemic level is one of the mechanisms allowing the tumor to evade the immune response. This mechanism does not have the same impact in all tumors, however, ovarian cancer itself determines the existence of the disease progress. The Treg cells inhibit effector cells by mechanisms dependent on cell-cell contact and the release of cytokines such as interleukin-10 and beta transforming growth factor. The result of this increase is helping to trigger the tolerance mechanisms to the immune system action, thereby associating with poor prognostic parameters. There is scientific evidence on the involvement of Treg lymphocytes in ovarian cancer, which have allowed the understanding the impact they have on this disease clinical features and prognosis, offering attractive new therapeutic targets that will improve this disease course.

REFERENCES

1. Dietl J, Engel JB, Wischhusen J. The role of regulatory T cells in ovarian cáncer. Int J Gynecol Cancer. 2007;17:764-70.

2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow. Lancet. 2001;357:539-45.

3. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Inmunol. 2012;13:343-51.

4. Chowa MT, Möllerb A, Smytha MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012;22(1):23-32.

5. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive Strategies that are Mediated by Tumor Cells. Annu Rev Immunol. 2007;25:267-96.

6. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer. 2012;12:307-13.

7. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.

8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454.

9. Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting: Integrating Immunity's Roles in Cancer. Science. 2011;331:1565-70.

10. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006;16:115--23.

11. Swann JB, Smyt MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-46.

12. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A. Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor. Immunity. 2009;30:899-911.

13. Pasqualini CD. Papel bivalente del sistema inmune en el crecimiento tumoral. Medicina (Buenos Aires). 2004;64(3):277-80.

14. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-64.

15. Sakaguchi S, Wing K, Onishi Y, Prieto-MartinP, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? International Immunology. 2009;10(21):1105-11.

16. Curotto MA, Lafaille JJ. Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a Division of Labor? Immunity. 2009;30.

17. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nature. 2010;10:490-500.

18. Jemal A, Siegel R, Ward E, Hao Y, Xu Jand, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225-49.

19. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. 2004 [consulta 2 Jul 2012]. Disponible en: http://www.nature.com/naturemedicine/10.1038/nm1093

20. Clarke-Pearson, DL. Screening for Ovarian Cancer. N Eng J Med. 2009;361:170-7.

21. Wicherek L, Jozwicki W, Windorbska W, Roszkowski K, Lukaszewska E, Wisniewski M, et al. Analysis of Treg Cell Population Alterations in the Peripheral Blood of Patients Treated Surgically for Ovarian Cancer. A Preliminary Report. Am J Reprod Immunol. 2011;66:444-50.

22. Zhao X, Ye F, Chen L, Lu W, Xie X. Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4+CD25"CD45RA+ naïve T cells to express forkhead box protein 3 and exhibit suppressive ability in vitro. Cancer Science 2009;100(11):2143-51.

23. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Rev Immunol. 2012;12:269-81.

24. Liu Z, Tian S, Falo LD , Sakaguchi S, You Z. Therapeutic Immunity by Adoptive Tumor-primed CD4+ T-cell Transfer in Combination With In Vivo GITR Ligation. Molecular Therapy. 2009;17(7):1274-81.

25. Malvicini M, Puchulo G, Matar P, Mazzolini G. Inmunoterapia del cáncer. Importancia de controlar la inmunosupresión. Medicina (Buenos Aires). 2010;70(6):565-70.

26. Peng DJ, Liu R, Zou W. Regulatory T Cells in Human Ovarian Cancer. J Oncol 2012. [consulta 20 Ago 2012]. Disponible en: http://www.hindawi.com/journals/jo/2012/345164/cta/

27. Gavalas NG, Karadimou A, Dimopoulos MA, Bamias A. Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy:Potential for Treatment Utilization. Clin Dev Immunol. 2010 [consulta 20 Ago 2012]. Disponible en: http://www.hindawi.com/journals/cdi/2010/791603 /cta/

28. Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ. Understanding the Cross-Talk between Ovarian Tumors and Immune Cells: Mechanisms for Effective Immunotherapies. Int Rev Immunol. 2011;30:71-86.